If you feel like it's hard to find venture capitalists in Houston, you wouldn't be wrong, according to this Houston investor. Photo via Getty Images

As a venture capitalist and former startup founder living in Houston, I get asked a lot about the best way to find and connect with a venture capitalist in Houston. My usual advice is to start with a list, and reach out to everyone on that list. But no one has a comprehensive list. In fact, VCs are such a quiet bunch that I’ve yet to meet someone who personally knows everyone on this proverbial list.

So, I got together with a couple of VC friends of mine, and we put together our own Houston venture capitalist list.

There are, by our count, 11 active venture capital funds headquartered in Houston of any size and type, and outside of corporate venture capital and angel investors, there are 30 total venture capitalists running funds.

Houston has always been quite thin on the VC fund front. I’ve jokingly introduced myself for a while as “one of the 13 venture capitalists in Houston.”

Let’s put this scale in some brutal perspective. With 7.2 million people in the Greater Houston Metro Area, the odds of finding a partner level active venture capitalist in Houston is about 1 in 240,000, if you take a most expanded definition of venture capitalist that might come down to 1 in 100,000. We’re the fifth largest metropolitan area in the country with a tremendous economic engine; there is a ton of capital in Houston, but it’s residing in things like institutional fixed income and equities, real estate, wealth management, corporate, private equity, family office, energy and infrastructure Basically, mostly everywhere but in venture capital funds for tech startups.

By comparison, there are almost as many Fortune 500 CEOs in Houston — 24, by our count — as venture capitalists and fewer venture capitalists than Fortune 1000 CEOs, of which there are 43. That means running into a VC in the checkout line at HEB is about as rare as running into the CEO of CenterPoint, ConocoPhillips, or Academy. In fact, as there are 115 cities in the Greater Houston area, you are three times more likely to be a mayor in Greater Houston Area than a partner at an investor at a VC firm, and more likely to be a college or university president. While we’re at it, you’re 400 times more likely to be a lawyer, 250 times more likely to be a CPA, and over 650 times more likely to be a medical doctor.

Our 30 venture capitalists in the Greater Houston Area are spread across 20 firms and all major venture sectors and stages. Venture capitalist is defined for this list as a full time managing director or partner-level investment professional actively running a venture capital fund with limited partners, currently investing in new venture capital deals from their fund from seed to growth stage, and residing in the Greater Houston Metro area.

To get to 31 we added in a couple of people running venture set asides for PE funds, and a number who work from Houston for funds with no office here. We excluded CVCs, as the decision making is more corporate than individual and rarely includes the committed fund and carried interest structure that defines venture capital, and excluded professionals at angel networks, accelerators, and seed funds that provide investment, but don’t manage conventional venture capital funds, as well as PE funds that do the occasional venture deal. We might be able to triple the number if we include venture capitalists at any professional level, and add in those professionals at PE and angel and seed funds, and corporate venture capital teams who are actively investing. But we’ll get to those other sources of funding in the next list.

The 11 venture capital funds headquartered in Houston are: Mercury, Energy Transition Ventures (my fund), Montrose Lane (formerly called Cottonwood), Texas Medical Center Venture Fund, Artemis, New Climate Ventures, Fitz Gate Ventures, Curate Capital, Knightsgate Ventures, Amplo Ventures,and First Bight Ventures.

Another half a dozen firms have a partner level venture capital investor here, but are headquartered elsewhere: Energy Innovation Capital, Decarbonization Partners, 1984 Ventures, Altitude Ventures, Ascension Ventures, Moneta Ventures, and MKB & Co. Two others, CSL Ventures and SCF Partners, are local private equity funds with a venture capital partner in Houston and a dedicated allocation from a PE fund.

Culling these for partner or managing director level currently in Houston, in alphabetical order by first name, LinkedIn profile and all.

We may have missed a couple of VCs hiding in plain sight, as venture capital is a pretty dynamic business.

VCs are just rare. And yes, perhaps more rare in Houston than in California. Something less than 1 in 100 VCs in the country live in Houston. Across the US there are somewhere around 1,000 to 2,000 active venture capital firms, and maybe another 1,000 to 2,000 active US based CVCs — so, plus or minus maybe at most 4,000 to 5,000 currently active partner level venture capitalists in the country excluding CVC professionals (active VCs and VC funds are really hard to count).

Perhaps in the most stunning statistic, the 7,386 elected state legislators in the US today outnumber the total number of American venture capitalists. Luckily for startup founders, the venture capitalists are more likely to return your phone call.

------

Neal Dikeman is a venture capitalist and seven-time startup co-founder investing out of Energy Transition Ventures. He’s currently hosting the Venture Capital for First Time Founders Series at the Ion, where ETV is headquartered.

What are health tech investors looking for these days? Thes VC experts weigh in. Photo via Getty Images

Here's what venture capital investors look for in Houston health tech

money talks

It's been a tumultuous year for health technology — and venture capital investment activity has definitely been affected. Looking toward the future, a group of panelists discussed how they are investing — and what they are looking for.

The panel, which was presented in partnership with the Houston Angel Network and Cooley for Houston Tech Rodeo, featured three investors:

  • Dennis McWilliams, partner at Santé
  • Terri Burke, venture partner at Epidarex Capital
  • Farzad Soleimani, health care partner at 1984 Ventures
Here's what these professionals consider when evaluating a potential deal.

A unique idea

The idea and solution of the med tech device or digital health company is of course of high importance for the investors.

"We really look for that unmet need. What is the innovative technology or med tech that's doing something different?" Burke says. "We try to find things that are breakthrough or disruptive that aren't one of six going after the same thing."

In light of COVID-19, the panelists discussed the advancement of remote care and telehealth. Another concern amid population growth is access to primary care doctors.

"Five years from now, we're going to be short like 60,000 to 70,000 primary care doctors," Soleimani says. "The only way we can close the gap is either to turn regular doctors into super doctors, and that's going to be driven by AI and data. ... Or, enabling other providers to act more like primary care doctors."

This type of innovation is top of mind for investors. What technology can help experts like pharmacists to provide care of this sort?

"We've seen a lot of investment going into enabling other providers to act as primary care doctors," Soleimani says. "They have the training."

A strong team

Much like startups, the people power the product growth. The panelists emphasized the importance of the potential team they'd be investing in, and it's something you learn over the diligence process.

​"You want to work with people you enjoy working with, so finding the right mix of people — whether we build it ourselves and help scale up a new company or a seasoned teams comes to us," Burke says.

For Soleimani, he is specific about making sure companies have someone in the CTO role — not just a part-time developer or contract worker.

"You need to have somebody who can build the technology — I cannot stress that enough," he says. "The process is arduous, and you're not going to get there overnight."

IP and regulatory process

Investors are looking to support protected technology, the panelists say, and most of the times they want an entrepreneur to start that process earlier than you might think.

"Investors actually care and care a lot and go pretty deep to make sure that something in the idea is protectable," Burke says.

The panelists also say they want a team that understands the regulatory process that will get the technology to scale. And investors aren't scared of investing in companies going down these paths.

"The regulatory process is often times misinterpreted — it can be your ally," Soleimani says. "Just because something needs to go through the regulatory process doesn't mean it is less attractive. It just has to be the right process for it."

McWilliams says a few years ago, maybe the process was more confusing, but nowadays companies are familiar with their options.

"For the most part, most devices know what the pathway is going to be," he explains. "If a team is telling you they don't really know what their regulatory strategy is, they probably don't know what they are doing or they don't want to tell you."

The panelists acknowledged that these regulatory processes can be costly, so factoring that into the equation is important. It's also a space where surrounding yourself with the right people is important.

"I think it's important to not only know your pathway, but also what it will take to prove that out," Burke says. "That's where physician advisers can be really valuable, as well as regulatory consultants."

The right valuation

Valuation is another factor investors consider — both valuations that are too high and too low.

"There's always this question of valuation and there's always this desire to maximize your pre-money valuation on a deal, and I would say that this can often times get you in really big trouble," McWilliams says.

Consider the market and where your company capitalization stands, McWilliams adds, and make sure there's always room on either side.

Ultimately, it depends on the investor

The panelists left the audience with advice for entrepreneurs to do their homework when reaching out to potential investors. Both what kind of companies investors fund as well as what stage they contribute to.

"It's important to know what type of investor you're speaking to," Burke says.

Starting those relationships with plenty of time is also important.

"It's hard to build a meaningful, lasting relationship with an investor if you're running of cash in two months and need a decision right away," McWilliams says.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston lab develops AI tool to improve neurodevelopmental diagnoses

developing news

One of the hardest parts of any medical condition is waiting for answers. Speeding up an accurate diagnosis can be a doctor’s greatest mercy to a family. A team at Baylor College of Medicine has created technology that may do exactly that.

Led by Dr. Ryan S. Dhindsa, assistant professor of pathology and immunology at Baylor and principal investigator at the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, the scientists have developed an artificial intelligence-based approach that will help doctors to identify genes tied to neurodevelopmental disorders. Their research was recently published the American Journal of Human Genetics.

According to its website, Dhindsa Lab uses “human genomics, human stem cell models, and computational biology to advance precision medicine.” The diagnoses that stem from the new computational tool could include specific types of autism spectrum disorder, epilepsy and developmental delay, disorders that often don’t come with a genetic diagnosis.

“Although researchers have made major strides identifying different genes associated with neurodevelopmental disorders, many patients with these conditions still do not receive a genetic diagnosis, indicating that there are many more genes waiting to be discovered,” Dhindsa said in a news release.

Typically, scientists must sequence the genes of many people with a diagnosis, as well as people not affected by the disorder, to find new genes associated with a particular disease or disorder. That takes time, money, and a little bit of luck. AI minimizes the need for all three, explains Dhindsa: “We used AI to find patterns among genes already linked to neurodevelopmental diseases and predict additional genes that might also be involved in these disorders.”

The models, made using patterns expressed at the single-cell level, are augmented with north of 300 additional biological features, including data on how intolerant genes are to mutations, whether they interact with other known disease-associated genes, and their functional roles in different biological pathways.

Dhindsa says that these models have exceptionally high predictive value.

“Top-ranked genes were up to two-fold or six-fold, depending on the mode of inheritance, more enriched for high-confidence neurodevelopmental disorder risk genes compared to genic intolerance metrics alone,” he said in the release. “Additionally, some top-ranking genes were 45 to 500 times more likely to be supported by the literature than lower-ranking genes.”

That means that the models may actually validate genes that haven’t yet been proven to be involved in neurodevelopmental conditions. Gene discovery done with the help of AI could possibly become the new normal for families seeking answers beyond umbrella terms like “autism spectrum disorder.”

“We hope that our models will accelerate gene discovery and patient diagnoses, and future studies will assess this possibility,” Dhindsa added.

Texas robotics co. begins new search for missing Malaysia Airlines flight 370

International News

Malaysia’s government has given final approval for a Texas-based marine robotics company to renew the search for Malaysia Airlines Flight 370, which is believed to have crashed in the southern Indian Ocean more than a decade ago.

Cabinet ministers agreed to terms and conditions for a “no-find, no-fee” contract with Texas-based Ocean Infinity to resume the seabed search operation at a new 5,800-square-mile site in the ocean, Transport Minister Anthony Loke said in a statement Wednesday. Ocean Infinity will be paid $70 million only if wreckage is discovered.

The Boeing 777 plane vanished from radar shortly after taking off on March 8, 2014, carrying 239 people, mostly Chinese nationals, on a flight from Malaysia’s capital, Kuala Lumpur, to Beijing. Satellite data showed the plane turned from its flight path and headed south to the far-southern Indian Ocean, where it is believed to have crashed.

An expensive multinational search failed to turn up any clues to its location, although debris washed ashore on the east African coast and Indian Ocean islands. A private search in 2018 by Ocean Infinity also found nothing.

The final approval for a new search came three months after Malaysia gave the nod in principle to plans for a fresh search.

Ocean Infinity CEO Oliver Punkett earlier this year reportedly said the company had improved its technology since 2018. He has said the firm is working with many experts to analyze data and had narrowed the search area to the most likely site.

Loke said his ministry will ink a contract with Ocean Infinity soon but didn’t provide details on the terms. The firm has reportedly sent a search vessel to the site and indicated that January-April is the best period for the search.

“The government is committed to continuing the search operation and providing closure for the families of the passengers of flight MH370,” he said in a statement.

Harris County booms with 3rd biggest population in U.S.

Boomtown

Newly released U.S. Census Bureau data has revealed Harris County became the third most populous county nationwide in 2024, and it had the highest year-over-year growth rate from 2023.

The new population report, published this month, estimated year-over-year population data from 2023 to 2024 across all 3,144 U.S. counties, and 387 metro areas.

Harris County's numeric growth rate outpaced all other U.S. counties from July 1, 2023 to July 1, 2024, the report found. The Census Bureau estimated Harris County's population grew by 105,852 people year-over-year, bringing the total population to 5,009,302 residents. That's around a 2.16 percent growth rate.

Los Angeles County, California (No. 1) and Illinois' Cook County (No. 2) are the only two U.S. counties that have larger populations than Harris County. Los Angeles County now boasts a population of nearly 9.76 million, while Cook County's has increased to more than 5.18 million people.

The top 10 most populous counties in the U.S. are:

  • No. 1 – Los Angles County, California
  • No. 2 – Cook County, Illinois
  • No. 3 – Harris County, Texas
  • No. 4 – Maricopa County, Arizona
  • No. 5 – San Diego County, California
  • No. 6 – Orange County, California
  • No. 7 – Miami-Dade County, Florida
  • No. 8 – Dallas County, Texas
  • No. 9 – Kings County, New York
  • No. 10 – Riverside County, California

Montgomery County also ranked among the top 10 U.S. counties with the highest numeric growth, ranking 9th nationally after gaining 34,268 residents from 2023 to 2024. Montgomery County's population has now grown to 749,613 people.

In the report's national comparison of counties with the largest population growth by percentage, Montgomery County ranked No. 7 with a year-over-year growth rate of 4.8 percent.

Most populated U.S. metro areas

The U.S. Census Bureau additionally found Houston-Pasadena-The Woodlands nearly led the nation as the second-fastest growing metro area in 2024.

From July 2023 to July 2024, the Houston metro added 198,171 residents to bring the total population to 7,796,182.

New York-Newark-Jersey City was the only metro area to outpace Houston's growth during the one-year period. The New York-New Jersey metro added 213,403 new residents, which brought the total population to over 19.94 million last year.

Kristie Wilder, a Census Bureau Population Division demographer, said in the report that the nation's population growth in its major metros was largely impacted by international migration rather than changes in birth rates.

"While births continue to contribute to overall growth, rising net international migration is offsetting the ongoing net domestic outmigration we see in many of these areas," Wilder said.

Dallas-Fort Worth-Arlington was right behind Houston as the third-fastest growing U.S. metro in 2024. The Metroplex gained 177,922 residents last year, and now has a total population of more than 8.34 million.

The top 10 U.S. metros with the highest numeric growth from 2023 to 2024 are:

  • No. 1 – New York-Newark-Jersey City, New York-New Jersey
  • No. 2 – Houston-Pasadena-The Woodlands, Texas
  • No. 3 – Dallas-Fort Worth-Arlington, Texas
  • No. 4 – Miami-Fort Lauderdale-West Palm Beach, Florida
  • No. 5 – Washington-Arlington-Alexandria, D.C.-Virginia-Maryland-West Virginia
  • No. 6 – Phoenix-Mesa-Chandler, Arizona
  • No. 7 – Orlando-Kissimmee-Sanford, Florida
  • No. 8 – Atlanta-Sandy Springs-Roswell, Georgia
  • No. 9 – Chicago-Naperville-Elgin, Illinois-Indiana
  • No. 10 – Seattle-Tacoma-Bellevue, Washington
---

This article originally appeared on our sister site, CultureMap.com.